Enzyme Evolution: An Epistatic Ratchet versus a Smooth Reversible Transition.


Journal

Molecular biology and evolution
ISSN: 1537-1719
Titre abrégé: Mol Biol Evol
Pays: United States
ID NLM: 8501455

Informations de publication

Date de publication:
01 04 2020
Historique:
pubmed: 25 12 2019
medline: 19 3 2021
entrez: 25 12 2019
Statut: ppublish

Résumé

Evolutionary trajectories are deemed largely irreversible. In a newly diverged protein, reversion of mutations that led to the functional switch typically results in loss of both the new and the ancestral functions. Nonetheless, evolutionary transitions where reversions are viable have also been described. The structural and mechanistic causes of reversion compatibility versus incompatibility therefore remain unclear. We examined two laboratory evolution trajectories of mammalian paraoxonase-1, a lactonase with promiscuous organophosphate hydrolase (OPH) activity. Both trajectories began with the same active-site mutant, His115Trp, which lost the native lactonase activity and acquired higher OPH activity. A neo-functionalization trajectory amplified the promiscuous OPH activity, whereas the re-functionalization trajectory restored the native activity, thus generating a new lactonase that lacks His115. The His115 revertants of these trajectories indicated opposite trends. Revertants of the neo-functionalization trajectory lost both the evolved OPH and the original lactonase activity. Revertants of the trajectory that restored the original lactonase function were, however, fully active. Crystal structures and molecular simulations show that in the newly diverged OPH, the reverted His115 and other catalytic residues are displaced, thus causing loss of both the original and the new activity. In contrast, in the re-functionalization trajectory, reversion compatibility of the original lactonase activity derives from mechanistic versatility whereby multiple residues can fulfill the same task. This versatility enables unique sequence-reversible compositions that are inaccessible when the active site was repurposed toward a new function.

Identifiants

pubmed: 31873734
pii: 5686393
doi: 10.1093/molbev/msz298
doi:

Substances chimiques

phosphorylphosphatase EC 3.1.3.-
Phosphoric Monoester Hydrolases EC 3.1.3.2
Aryldialkylphosphatase EC 3.1.8.1
PON1 protein, human EC 3.1.8.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1133-1147

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Moshe Ben-David (M)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.

Misha Soskine (M)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.

Artem Dubovetskyi (A)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.

Kesava-Phaneendra Cherukuri (KP)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.

Orly Dym (O)

Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.

Joel L Sussman (JL)

Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.

Qinghua Liao (Q)

Department of Chemistry - BMC, Uppsala University, Uppsala, Sweden.

Klaudia Szeler (K)

Department of Chemistry - BMC, Uppsala University, Uppsala, Sweden.

Shina Caroline Lynn Kamerlin (SCL)

Department of Chemistry - BMC, Uppsala University, Uppsala, Sweden.

Dan S Tawfik (DS)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH